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RESEARCH ARTICLE
Small extracellular vesicles modulated by αVβ3 integrin induce neuroendocrine
differentiation in recipient cancer cells
Fabio Quagliaa,b, Shiv Ram Krishna,b, George G. Daaboulc, Srawasti Sarkera,b, Raffaella Pippad, Josep Domingo-
Domenechd, Gaurav Kumarb, Paolo Fortinab, Peter McCuee, William K. Kellyd, Himisha Beltranf, Qin Liu g
and Lucia R. Languinoa,b
aProstate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA; bDepartment of Cancer Biology,
Thomas Jefferson University, Philadelphia, PA, USA; cDepartment of Research and Development, NanoView Biosciences, Boston, MA, USA;
dDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA; eDepartment of Pathology, Thomas Jefferson
University, Philadelphia, PA, USA; fDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA,
USA; gMolecular and Cellular Oncogenesis Program, the Wistar Institute, Philadelphia, PA, USA
ABSTRACT
The ability of small extracellular vesicles (sEVs) to reprogram cancer cells is well established.
However, the specific sEV components able to mediate aberrant effects in cancer cells have not
been characterized. Integrins are major players in mediating sEV functions. We have previously
reported that the αVβ3 integrin is detected in sEVs of prostate cancer (PrCa) cells and transferred
into recipient cells. Here, we investigate whether sEVs from αVβ3-expressing cells affect tumour
growth differently than sEVs from control cells that do not express αVβ3. We compared the ability
of sEVs to stimulate tumour growth, using sEVs isolated from PrCa C4-2B cells by iodixanol
density gradient and characterized with immunoblotting, nanoparticle tracking analysis, immu-
nocapturing and single vesicle analysis. We incubated PrCa cells with sEVs and injected them
subcutaneously into nude mice to measure in vivo tumour growth or analysed in vitro their
anchorage-independent growth. Our results demonstrate that a single treatment with sEVs shed
from C4-2B cells that express αVβ3, but not from control cells, stimulates tumour growth and
induces differentiation of PrCa cells towards a neuroendocrine phenotype, as quantified by
increased levels of neuroendocrine markers. In conclusion, the expression of αVβ3 integrin
generates sEVs capable of reprogramming cells towards an aggressive phenotype.
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Introduction
Extracellular vesicles (EVs) are particles that are delim-
ited by a lipid bilayer and that are released from cells
[1]. In this manuscript, we define small EVs (sEVs) as
those particles isolated from cell supernatants using
iodixanol density gradients, as well as vesicles isolated
from the plasma of TRAMP mice through differential
centrifugation. We further define sEVs predominantly
by their size (50–150 nm in diameter), and their
enrichment of specific proteins, such as CD9, CD63,
CD81, TSG101 and ALIX [1,2].
sEVs are involved in regulating a variety of cellular
processes, including adhesion, migration, proliferation
and differentiation, and they carry integrins [3–5].
Integrins, which are transmembrane receptors com-
posed of two subunits, termed α and β, appear to
play a role in cancer, as indicated by various studies
that have shown altered integrin composition in cells
during cancer, including prostate cancer (PrCa),
progression [6,7]. For example, it has been reported
that some β1 integrin heterodimers are downregulated
in PrCa [8], while αVβ1, αVβ6 and α6β1 integrins are
overexpressed in PrCa [9–12].
The αVβ3 integrin is usually present at very low
levels in normal human prostate cells but is highly
expressed in PrCa cells and metastasis, and is believed
to promote invasion and adhesion of cancer cells to
extracellular matrix proteins, such as vitronectin
[7,13,14]. Given its widespread distribution in PrCa,
αVβ3 has been explored as a therapeutic target in
some studies [15,16]; however, its role and expression
have not been explored in the most aggressive forms
of PrCa, such as neuroendocrine PrCa (NEPrCa).
NEPrCa is an aggressive subtype of PrCa that typi-
cally develops from subsets of castrate-resistant PrCa
(CRPrCa) [17]. NEPrCa does not express androgen
receptor (AR) or prostate-specific antigen (PSA) but
does express neuron-specific proteins, such as aurora
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kinase A (AURKA), synaptophysin (SYP), and neuron
specific enolase (NSE) [18] that activate pro-
tumorigenic pathways independently from the AR
[19,20]. NEPrCa frequently metastasizes, responds
poorly to chemotherapy, and is often associated with
poor prognosis, with a life expectancy of less than
one year [21]. How PrCa differentiates into NEPrCa
is unclear; this knowledge is particularly important
for understanding the onset of NE differentiation
(NED) and developing new therapeutic strategies to
block it.
Here, we describe studies designed to shed light on
the role of αVβ3-containing sEVs in PrCa, and parti-
cularly in NEPrCa. We show, for the first time, that
sEVs, isolated using iodixanol density gradients from
CRPrCa cells that express αVβ3, promote tumour
growth and induce NED in recipient cancer cells both
in vivo and in vitro. Conversely, sEVs isolated from
CRPrCa cells that do not express αVβ3 exert a minimal
effect on tumour growth. Overall, we demonstrate that
the cellular expression of αVβ3 integrin generates sEVs




C4-2B β3, C4-2B Mock, C4-2B β3-GFP, C4-2B Mock-
GFP,DU145, PC3, LNCaP andLNCaPβ3 cells, and culture
conditions have been previously described [5,22,23].
Antibodies
The following antibodies (Abs) were used for immu-
noblotting (IB) analysis: mouse monoclonal Abs
against: CD9 (Santa Cruz, sc18869), CD63 (Abcam,
ab8219), CD81 (Abcam, ab23505), SYP (Dako,
M0776) and ALIX (Abcam, ab117600); rabbit polyclo-
nal Abs against: TSG101 (Abcam, ab30871) and CANX
(Santa Cruz, sc-11397); rabbit monoclonal Ab against
AURKA (Cell Signalling, D3E4Q). A rabbit polyclonal
Ab against the cytoplasmic domain of the human β3
subunit has been described [13]. For immunofluores-
cence assays, AP3 mouse monoclonal Ab against β3
(ATCC) was used. For immunohistochemistry analysis,
rabbit monoclonal Ab against β3 integrin (Cell
Signalling, 13166 S) and rabbit monoclonal Ab against
synaptophysin (SP11, Ventana, 790–4407) were used.
For sEV treatments, mouse monoclonal Ab against
αVβ3 integrin (LM609, Millipore MAB1976) and
mouse IgG1 (Thermo Scientific, 31202) were used.
For ExoView assays, the following NanoView
Biosciences Abs were used: CD81 (JS-81), CD63
(H5 C6), CD9 (HI9A), CD41 (HIP8) and mouse IgG1
(MOPC-21); also, EpCAM (9C4, Biolegend) and β3
integrin/CD61 (VIPL2, BD Biosciences) were used.
sEV isolation by differential centrifugation
Isolation of sEVs from C4–2B β3, C4–2B Mock, C4–2B
β3-GFP and LNCaP β3 cells was performed as pre-
viously described [2,22,23]. The culture supernatant
(SN) was collected after 48 h of serum starvation and
processed by differential ultracentrifugation. The SN
was first precleared of dead cells and debris by centri-
fugation at 2000 × g for 20 min at 4°C. The SN was
then transferred to a fresh ultracentrifuge tube and
centrifuged at 10,000 × g for 35 min at 4°C. The
remaining SN was then centrifuged at 100,000 × g for
70 min at 4°C. The pellet was further washed in PBS,
followed by a filtration step using 0.22 μm filters
(Milex®GP, Millipore #SLGP033RS) and a second
wash at 100,000 × g for 70 min at 4°C. The final pellet
(P100) was resuspended in 1×PBS for storage at – 80°C
and subsequent nanoparticle tracking analysis (NTA)
and immunoblotting (IB). Total cell lysates and sEV
lysates were prepared in RIPA buffer.
sEV isolation from TRAMP (transgenic
adenocarcinoma of the mouse prostate) mouse
plasma
Male TRAMP mice were used in this study. For
TRAMP: n = 3; for Wild-Type: n = 3. At 20 weeks of
age, when palpable tumours have formed, the blood
was collected through intracardiac withdrawal from the
animals and the plasma was isolated by centrifuging
the blood at 16,100 × g for 30 min at 4°C. Using 500 μL
of plasma, the sEVs were isolated as described above.
Care of animals was in compliance with standards
established by the Office of Laboratory Animal
Welfare, Department of Health and Human Services
at NIH. Experimental protocols were approved by the
Institutional Animal Care and Use Committee
(IACUC) at Thomas Jefferson University.
Iodixanol density gradient
The P100 pellets, isolated from the differential centri-
fugations described above, were subjected to iodixanol
density gradient isolation as previously described
[5,24]. The 30%, 20% and 10% wt/vol iodixanol solu-
tions were prepared by diluting a stock solution (60%
wt/vol) of iodixanol (OptiPrep™, Sigma #1556) with
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a buffer solution (0.25 M sucrose, 10 mM Tris, 1 mM
EDTA, pH 7.4). The P100 was mixed with stock iodix-
anol solution to generate 1.6 mL of 30% iodixanol-
P100 suspension and loaded at the bottom of
a SW55Ti rotor tube (Beckman). Next, 0.7 mL of 20%
and 0.7 mL of 10% (wt/vol) iodixanol were successively
layered on top of the 30% iodixanol-P100 suspension
to generate a discontinuous iodixanol density gradient.
The tubes were then centrifuged for 70 min at
350,000 × g, 4°C, in a SW55Ti rotor using a Beckman
L8–70M Ultracentrifuge. Ten fractions of 260 μL each
were then collected, starting from the top of the tube.
The density of each fraction was assessed with an
ABBE-3L refractometer (Fisher Scientific). All fractions
were diluted and washed with 1 mL PBS and centri-
fuged for 2 h at 100,000 × g, 4°C, in a TLA-100.2 rotor
using a Beckman Optima TL Ultracentrifuge. The
resulting pellets for each fraction were re-suspended
in 30 μL of PBS and stored at −80°C until further use.
Immunoblotting (IB) analysis
The total protein concentration of sEVs was determined
using BioRad DCTM protein assay kit as per the manufac-
turer’s protocol. Equal amounts of proteins (7–50 μg) were
separated by 12.5% sodium dodecyl sulphate-polyacryla-
mide gel electrophoresis (SDS-PAGE), transferred to
PVDF membranes (Immobilon-E PVDF membrane,
Millipore), blocked with blocking buffers (5% non-fat dry
milk in Tris Buffer Saline with 0.1% Tween 20 [TBST]) for
1 hour at room temperature, incubated overnight
(16 hours) with primary Abs at 4°C followed by TBST
washes (4 × 5 min) at room temperature, then incubated
with horseradish peroxidase (HRP)-conjugated anti-
mouse or -rabbit secondary Abs for 1 hour at room tem-
perature, followed by TBST washes (4 × 5 min) at room
temperature. For visualization, WesternBrightTM ECL
HRP substrate kits (Advansta Inc., CA, USA) were used.
Nanoparticle tracking analysis (NTA)
NTA (NS300, Malvern Instruments, MA) was used to
determine the size distribution and concentration of
sEVs released from C4-2B β3, C4-2B Mock, C4-2B
β3-GFP and C4-2B Mock-GFP cells. Briefly, sEV sus-
pensions were diluted 1:1000 in PBS, and the analysis
was performed using camera level settings ranging
from 11 to 13 to avoid saturation (coloured pixels).
Using the standard measurement, described in the
NTA software SOP, video files of 30 or 60 s (repeated
3 or 5 times) were captured with a frame rate of 25
frames per second of particles moving under Brownian
motion at a temperature ranging between 22°C and 25°
C. The analysis of videos was performed at a detection
threshold ranging from 3–5, NTA software version
3.1.54.
Detection and characterization of αVβ3 on sEVs
using SP-IRIS (single particle interferometric
reflectance imaging sensor)
Immunocapturing and digital detection of the sEVs was
performed as described in Daaboul et al. [25]. Briefly,
NanoView Biosciences produced chips with capture Abs
against human CD63, CD81, CD9, CD41 and EpCAM
together with the negative control IgG. For technical
replicates, the Abs were spotted on the chips in quadru-
plicate. All samples were diluted in the NanoView
Biosciences Solution A before being incubated on the
ExoView chip arrayed with the capture Ab. The samples
were incubated on the chip for 16 h at room temperature
in a sealed 24-well plate. The chips were then washed
three times in 750 µL of Solution A for 3 min each on an
orbital shaker. Then the chips were incubated with
a fluorescent β3 integrin Ab labelled with CF555 diluted
to a final concentration of 0.1 µg/mL in Solution A with
2% BSA for 1 h. The chips were then washed once in
NanoView Solution A, three times in NanoView Solution
B followed by a rinse in filtered DI water and dried. The
chips were then imaged with the ExoView R100 reader
using nScan 2.8.4 acquisition software. The data were
then analysed using NanoViewer 2.8.11 with sizing
thresholds set to 50 to 200 nm diameter. To normalize
the particle count between different capture Abs, the
analysis area was restricted to the area of a circle with
a diameter of 150 µm.
Immunofluorescence (IF) analysis
DU145 cells (150,000) were grown in 12-well plates and
serum-starved for 24 h before incubation with 20 μg
(corresponding to ~6 × 1010 particles) of sEVs isolated
using iodixanol density gradients from C4-2B β3-GFP
cells or C4-2B Mock-GFP cells. After 16-h incubation,
cells were detached and plated on glass coverslips coated
with 10 μg/mL human plasma vitronectin and allowed to
attach for 4 h. Cells were then washed with PBS (2
washes), fixed with 4% PFA for 15 min at room tempera-
ture, washed with PBS (3 washes), quenched with
50 mmol/L NH4 Cl for 15 min, permeabilized with
0.25% Triton-100 for 10 min, blocked for 1 h using 5%
BSA in PBST (PBS and 1% Tween 20), followed by over-
night incubation with primary Ab (AP3, anti-β3) in
blocking solution at 4°C. After overnight incubation, the
coverslips were washed with PBS (3 washes) and incu-
bated with secondary Ab (Goat anti mouse, Alexa 546)
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for 1 h and washed three times with PBST. The glass
coverslips were mounted on glass slides using ProLong™
diamond antifade containing DAPI (Invitrogen). The
slides were analysed, and images were captured by
a Nikon A1 R confocal microscope. A Z-stack image
analysis using imaging software ImageJ FIJI (version
4.11.0) was also performed to evaluate sEV internaliza-
tion into DU145 cells.
Anchorage-independent growth assay
DU145 and PC3 cells after sEV treatment were assayed
for anchorage-independent growth. DU145 cells
(300,000) were plated in 6-well plates and serum-
starved for 5 h. After starvation, cells were treated over-
night (16 h) in serum-free media with 109 sEVs isolated
by iodixanol gradient from C4-2B β3 or C4-2B Mock.
When LM609 or IgG was used, 109 sEVs isolated by
iodixanol gradient were pre-treated with 5 μg/mL of
LM609 mAb or IgG for 24 h at 4°C. Then, this mixture
was added to the starved cells. The next day, new 6-well
plates were coated with 0.8% agarose to create a bottom
layer. Treated cells were trypsinized, and 10,000 cells
from each well were resuspended in 2 mL of complete
medium (DMEM containing 10% FBS, 100 μg/mL strep-
tomycin, and 100 U/mL penicillin). The cell suspension
was then mixed with 0.2 mL of 3% agarose and layered
gently on top of the basement layer to seed cells in a final
concentration of 0.3% soft agar matrix. After solidifica-
tion, 0.5 mL of complete medium was added. Each
experimental condition was repeated three times. After
3 weeks, the image of the entire well was captured using
a Keyence BZ-x710microscope at 40×magnification, and
the average colony area of all detectable colonies was
measured using Fiji ImageJ [26].
In vivo effects of sEVs
DU145 cells (2.5 × 107) were treated for 16 h in serum-
free media with 8 × 1010 αVβ3 sEVs or Mock sEVs
isolated by iodixanol gradient. After incubation, the
sEVs were removed by washing the cells two times
with PBS. The cells were then maintained for 24 h in
complete medium, and 2 × 106 cells from each treat-
ment group were subcutaneously injected into nine
male nude mice (6 week-old, Taconic #NCRNU-M).
Tumour growth was monitored twice a week for
74 days using a caliper, and the tumour volume calcu-
lated by the following formula:
x ¼ H xW x L
2
Where H is height, W is width and L is length of
the tumour. After 74 days, all mice were euthanized.
The tumours collected were either lysed using RIPA
buffer and analysed by IB or processed as blocks
fixed in formalin and embedded in paraffin for
immunohistochemistry. The care and handling of
animals followed IACUC experimental protocols.
In vitro effects of sEVs on NE marker expression
DU145 and PC3 cells (300,000) were plated in 10 cm
plates and serum starved for 5 h. After starvation, cells
were treated overnight (16 h) in serum-free media with
109 sEVs isolated by iodixanol gradient from C4-2B β3
or C4-2B Mock cells. Then, this mixture was added to
the starved cells. After the sEV treatment, the cells were
washed with PBS and kept in complete medium. The
cell pellets were lysed and stored at −80°C until IB
analysis.
Human subject inclusion criteria
The bone metastasis specimens from prostate cancer
patients (n = 8) were provided by the Thomas
Jefferson University, Sidney Kimmel Cancer Center
Biorepository, a College of American Pathologists
(CAP) accredited biorepository. All specimens were
de-identified and discarded in accordance with IRB-
approved protocols.
Immunohistochemistry (IHC)
IHC was performed on tissue sections from tumours gen-
erated in nude mice subcutaneously injected with DU145
cells treated with equal numbers of sEVs isolated using
iodixanol density gradients from C4-2B β3 or C4-2B
Mock cells, or on human bone metastasis samples.
Decalcification of the human bone metastasis was per-
formed for 24–48 h at 4°C with 0.5M EDTA in dH2
O (Sigma) with a ratio of EDTA solution to tissue of 20:1.
The tissue sections were baked at 60°C for 1 h, followed by
deparaffinization with xylene (3min × 2), rehydrationwith
a graded alcohol series (100%, 90%, 70%, 50%, 30% for
3 min each) followed by deionized water (3 min × 2). The
sections were incubated with 3% H2O2 solution for
quenching endogenous peroxidase activity, followed by
heat-induced antigen retrieval with citrate buffer (10 mM
sodium citrate, 0.05% Tween 20, pH 6.0) at 95°C for
15 min. Sections were washed once with deionized water
for 5 min, followed by PBS wash for 5 min, and blocked
with 5% goat serum in PBST for 2 h. The tissue sections
were incubated overnight at 4°C with an Ab β3 integrin
(1:25), or Rabbit-IgG (RbIgG) as negative control. The
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following day, the tissue sections were washed with PBST
(5 min × 2), followed by PBS (5 min), and incubated with
secondary Ab (Biotinylated Goat Anti-Rabbit IgG, 10 μg/
mL in PBST) for 30 min at room temperature. The
unbound secondary Ab was washed with PBST (5 min
× 2), followed by PBS (5 min). The tissue sections were
incubated with streptavidin horseradish peroxidase (SAP,
5 μg/mL in PBS) for 30 min at room temperature. The
unbound SAPwaswashedwith PBST (5min× 2), followed
by PBS (5 min). The colour was developed by adding
substrate chromogen, 3,3′-diaminobenzidine solution
(DAB substrate kit). The DAB reaction was stopped by
rinsing the tissue sections in deionized water. The sections
were counterstainedwithHarris haematoxylin, dehydrated
in a graded ethanol series (30%, 50%, 70%, 90%, 100% for
5 min each) followed by xylene (5 min × 2), dried, and
finally mounted with Permount (Vector Laboratories).
Synaptophysin staining was performed on an automated
VENTANA Discovery XT staining instrument according
to the manufacturer’s recommendations. Briefly, antigen
retrieval was performed on the Roche Discovery ULTRA
staining platform using Discovery CCI (Roche cat#950-
500) for a total application time of 36 min. Primary immu-
nostaining was performed using synaptophysin (SP11)
(Roche cat#790-4407) at 36°C for 32 min. Secondary
immunostaining used a horseradish peroxidase (HRP)
multimer cocktail (Roche cat#760-500) and immune com-
plexes were visualized using the ultraView Universal DAB
Detection Kit (Roche, 760–500). Slides were then washed
with a Tris-based reaction buffer (Roche cat#950-300) and
counterstained with Haematoxylin II (Ventana cat #790-
2208) for 4 min.
At least two members of the team reviewed each
tumour section. The β3 Integrin staining quantification
in Figure 5(c) was performed using the Fiji ImageJ
“color deconvolution” tool. The DAB image intensity
was measured, and the OD (Optical Density) calculated
using the following formula:
OD ¼ log max intensity
mean intensity
where max intensity is 255 for an 8-bit picture.
Data mining of publicly available dataset
The Neuroendocrine Prostate Cancer dataset [19]
from the cBio Cancer Genomics Portal (https://www.
cbioportal.org/) was used to obtain the mutation pro-
file for the ITGB3, SYP, AURKA, ITGB6 and ITGAV
genes. Only the samples corrected for “putative copy-
number alterations adjusted by ploidy and purity with
CLONET” were used to obtain genomic alterations in
the studied genes.
Statistical Analysis
Colony areas were log10 transformed before data
analysis to improve normality and homoscedasticity.
ANOVA with post-hoc Tukey’s multiple compari-
sons were performed and adjusted P-values were
reported for between groups’ comparisons. Means,
standard errors, medians, and interquartile ranges
were calculated, and Student’s t-test or Wilcoxon
rank sum test was used for two-group comparative
analyses for continuous outcomes. To determine if
treatments induced significant differences in tumour
growth in vivo, the velocities of tumour growth were
compared between groups using a linear mixed-
effects model with both random intercept and ran-
dom slopes at mouse level. A likelihood ratio testing
nested models (with versus without the interaction
term of treatment with follow-up days) was used to
examine if tumour growth slopes are overall signifi-
cantly different between treatments. P < 0.05 was
considered statistically significant.
Quantitative PCR with reverse transcription
Total RNA was extracted from sEVs using RNeasy®
Mini Kit (Qiagen, 74,106) following the manufacturer’s
instructions. The RNA thus obtained (270 ng) was
reverse transcribed using random hexamers (50 pmol,
Invitrogen 100,026,484) and the Super Script™ II
Reverse Transcriptase (Invitrogen, 18064-022) kit fol-
lowing the manufacturer’s instructions. Finally, mRNA
for ITGB3 (FW: ATT GGC CTT GCC GCC CTG CTC
and RW: ATC ATT AAG TGC CCC GGT ACG) and
GAPDH (FW: GGG AAG GTG AAG GTC GGA GT
and RW: GTT CTC AGC CTT GAC GGT GC) were
quantified by qPCR using PowerUP™ SYBR™ Green
Master Mix (Applied biosystems, MAN0013511) as
per the manufacturer’s instructions except that the
number of cycles was increased from 40 to 50.
Results
Characterization of αVβ3-positive and
αVβ3-negative sEVs from prostate cancer cells
We hypothesized that the expression of molecules in sEVs
might affect the function of these vesicles. We focused our
study on αVβ3, an integrin known to be present in sEVs
[22,23,27], and we thus performed our analysis by
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comparing sEVs containing αVβ3 to sEVs that lack this
integrin. We isolated sEVs from C4-2B CRPrCa cells that
express αVβ3, using iodixanol density gradients to remove
any possible debris resulting from the differential centrifu-
gation method (Figure 1(a)). The fractions containing
αVβ3 integrin, CD63, and CD81 were pooled and further
characterized for other EV markers (Figure 1(b)).
Immunoblotting (IB) analysis confirms the enrichment of
the known EV markers TSG101, CD81, CD9 and ALIX in
the isolated sEVs. Calnexin is used as negative control. The
vesicles thus isolated also contain AR, but there is no
difference in AR expression in the vesicles from C4-2B β3
or C4-2B Mock. Finally, nanoparticle tracking analysis
(NTA) confirms that the vesicles isolated using this
approach fall in the expected sEV size range of
100–150 nm (Figure 1(c)).
To confirm the presence of αVβ3 in the sEVs iso-
lated using iodixanol density gradients, we used the
ExoView assay (Figure 2). This assay allows us to
both phenotype and digitally count various populations
Figure 1. Characterization of αVβ3 sEVs and Mock sEVs isolated by iodixanol density gradient. (a) αVβ3 sEVs and Mock sEVs were
isolated by differential centrifugation and iodixanol density gradient from the culture medium of C4-2B β3 and C4-2B Mock cells. Then, the
sEVs were analysed by IB for β3, and sEV markers CD63, CD81. IB analysis was performed under non-reducing conditions. Calnexin (CANX),
which is supposed to be absent in sEVs, was also analysed. (b) Fractions 1–5 for αVβ3 sEVs, and 1–6 for Mock sEVs from the iodixanol density
gradients shown in (a) were pooled and further characterized to confirm expression of Androgen Receptor (AR), β3, TSG101, CD81, CD9 (left
panel); ALIX and calnexin (right panel). IB analysis was performed under reducing conditions. (a and b, TCL = total cell lysate). Different gels
were used to separate samples under reducing or non-reducing conditions. (c) NTA analysis of the pooled fractions characterized in (b).
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of the sEVs captured on a microarray-based chip using
different Abs against CD63, CD81, CD9, CD41 (αIIb)
and EpCAM. To determine the number of vesicles
positive for αVβ3, the immunocaptured vesicles on
the chip were labelled with a fluorescent Ab against
αVβ3. Our results show that when an Ab against one of
the tetraspanins, which form complexes with integrins,
was used to capture the sEVs on the chip, a clear signal
for αVβ3 integrin was observed. On the other hand,
when Ab to CD41 (or the isotype control) was used to
capture the vesicles, αVβ3 integrin was not detectable
(Figure 2(a)). Moreover, we were able to detect αVβ3
when the EpCAM Ab was used for immunocapturing
the sEVs, as previously reported by our group [5]. We
validated our ExoView assay findings using vesicles
from LNCaP αVβ3 cells (Figure 2(b)). Our results
clearly show that αVβ3 integrin is in the sEVs and is
not co-isolated with them during the isolation process.
Figure 2. Digital detection of αVβ3 on sEVs using SP-IRIS (Single Particle Interferometric Reflectance Imaging Sensor). sEVs
were isolated by differential centrifugation and iodixanol density gradient and analysed by SP-IRIS. (a) Left panel, C4-2B β3 sEVs
captured on the chip by the Ab indicated on the x-axis were visualized using a fluorescent β3 integrin Ab labelled with CF555. The
normalized number of particles is shown in the bar graph. Right panels, the αVβ3 integrin positive sEVs captured on the chip were
visualized. Representative images of the sEVs captured on the chip are shown; the top right panel shows sEVs captured on the chip
using CD81 Ab; the bottom right panel shows the sEVs captured on the chip by the isotype control. The bar represents 5 μm. (b)
The normalized number of particles positive for αVβ3 integrin from LNCaP β3 sEVs is shown. (a-b) The number of particles was
normalized as described in the Material and Methods section.
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In parallel, we tested the ability of the sEVs to transfer
αVβ3 into recipient cells. First, we isolated sEVs from C4-
2B β3-GFP cells, which express a fluorescent GFP-tagged
β3 integrin subunit, using iodixanol density gradients (Fig.
S1A) as described above. NTA analysis of αVβ3-GFP sEVs
exhibits a similar particle size range as αVβ3 sEVs (Fig.
S1B). IB analysis confirmed the presence of αVβ3-GFP
(approximately 125 kDa) in the C4-2B β3-GFP cells (Fig.
S1B). The sEVs were then incubated with DU145, a widely
used human prostate cancer cell line, for 16 h in serum-free
conditions; after this period, the cells were fixed and
observed using a confocal microscope (Figure 3). Under
the conditions used in our experiment, about 20% of the
cells were able to uptake either αVβ3-GFP sEVs or Mock-
GFP sEVs. In these cells, confocal Z-stack analysis confirms
the intracellular localization of the sEVs (Figure 3) as well
as colocalization of αVβ3 (red signal) and GFP (green
signal), thus indicating that αVβ3-GFP had been taken up
by the cells (Figure 3 and S2).
αVβ3 sEV treatment stimulates anchorage-
independent growth in vitro
To assess the effects of αVβ3-positive sEVs on other cells,
we treated 300,000DU145or PC3, another humanprostate
cancer cell line, cells with 109 αVβ3 sEVs or Mock sEVs
from C4-2B cells for 16 h under serum-free conditions
(Figure 4). After treatment, the cells were embedded in
0.3% agar and allowed to grow for 21 days. After this
period, the colony size was measured. We observe that
αVβ3 positive sEVs increase the colony size of DU145 or
PC3 cells when compared to the control cells pre-treated
with αVβ3-negative sEVs (Figure 4(a,b)). There was no
significant difference in the number of colonies between
the treatments used in this experiment (data not shown).
These results indicate that αVβ3 sEVs can reprogram PrCa
cell behaviour (by stimulating anchorage-independent
growth) after a single treatment and that their effects per-
sisted for at least 21 days (Figure 4(a)). Moreover, we pre-
treated our sEVs (αVβ3 sEVs or Mock sEVs) with the Ab
LM609 that binds specifically to αVβ3 [28] and has been
reported to be inhibitory [29,30]. The pre-treatment of the
sEVs with LM609 had no effects on the stimulation of
anchorage-independent growth of DU145 and PC3 cells
induced by the treatment with αVβ3 sEVs (Figure 4(a)),
indicating that the uptake of sEVs is not mediated by αVβ3
on the vesicles. We conclude that the increased expression
of αVβ3 in the donor cells (C4-2B) causes a change in the
composition of the vesicles that stimulates anchorage-
independent growth.
To confirm these findings, we performed an experi-
ment in which DU145, PC3 and LNCaP cells were treated
for 16 h with αVβ3 or Mock sEVs; the same cells/sEVs
ratio was used throughout our experiments (300,000
cells/109 sEVs). Cells were lysed immediately after the
treatment and at 21 days after the treatment.We observed
that, when these three PrCa cell lines were treated with
αVβ3 sEVs, the levels of SYP are increased. On the other
hand, Mock sEV treatment do not induce an increase in
this NEmarker in any of the cell lines (Figure 4(c)). These
results show that treatment with αVβ3 sEVs induces NED
in PrCa cells. When analysed using IB, the AR is not
transferred from the sEVs to the AR-negative cell lines
DU145 or PC3 (data not shown), nor are the levels of AR
increased in LNCaP cells (Figure 4(c)). However, AR is
downregulated in LNCaP 21 days post-treatment with
αVβ3 sEVs, and this decrease in AR levels correlates
with SYP upregulation (Figure 4(c)). Moreover, the β3
Figure 3. Uptake by DU145 cells of αVβ3 positive and negative sEVs isolated using iodixanol density gradients.
Immunofluorescence analysis of αVβ3 transfer to DU145 cells. DU145 cells (150,000) incubated with 20 μg (corresponding to
~6 × 1010 particles) sEVs derived from C4-2B β3-GFP cells (left panel) or C4-2B Mock-GFP (right panel) were plated on vitronectin-
coated coverslips. Arrows indicate GFP. The Z-stack analysis confirmed the intracellular colocalization of a red fluorescent signal
(AP3, β3 Ab) and a green fluorescent signal corresponding to GFP, indicating the internalization of β3-GFP from sEVs. DAPI was used
to detect cell nuclei (blue). The bar represents 10 μm. Seventy-eight cells were examined for each treatment group; 15–16 cells
were positive for GFP in both treatments.
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Figure 4. Stimulation of anchorage-independent growth and induction of synaptophysin by αVβ3 sEVs in vitro.
(a) Quantification of anchorage-independent growth expressed as log10 of the average colony area. sEVs (10,000 cells/3.3 × 10
6
sEVs) were incubated with LM609 Ab, mouse IgG or with PBS for 24 h and then, added to DU145 (left panel) or PC3 (right panel)
cells for 16 h. The cells then were embedded in 0.3% agar-containing complete medium and were allowed to grow for 3 weeks. The
average colony area was measured as described in the Materials and Methods section. Mock+609 and β3+609 indicate that the sEVs
used to treat DU145 and PC3 cells were incubated with the monoclonal Ab LM609 against αVβ3 Integrin, as described in the
Material and Method section. Mock+IgG and β3+IgG indicate that the sEVs used to treat DU145 and PC3 cells were incubated with
mouse IgG used as negative control. The first 3 groups were incubated with PBS, Ab LM609 or mouse IgG without sEVs; the
remaining groups were incubated with sEVs. (b) Representative images of the data quantified in (a). The bar represents 0.5 mm.
(c) IB analysis of synaptophysin (SYP) expression in DU145, PC3, and LNCaP recipient cells after 16 hour treatment with either αVβ3
or Mock sEVs (16 h) and 21 days after treatment (21dd). LNCaP lysates were also tested for AR expression. Actin was used as loading
control.
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integrin subunit is not detected in the recipient cells using
IB analysis or through qPCR (data not shown). In con-
clusion, the sEVs fromC4-2B cells that express high levels
of αVβ3 integrin induce SYP expression and reduce the
expression of AR in the recipient cells.
αVβ3 sEV treatment induces NED in DU145
cells in vivo
Based on these results, we tested the effects of
αVβ3-positive sEVs in vivo using a mouse model of
tumour growth. For this experiment, we pre-treated
2.5 × 107 DU145 cells for 16 h with 8 × 1010 sEVs
isolated by iodixanol gradient for each group (αVβ3 or
Mock). The sEV-treated cells (2 × 106) were subcuta-
neously injected into 6-week-old male nude mice, and
the tumour growth was monitored twice a week for
approximately 10 weeks. When the injected cells had
been treated with αVβ3 sEVs, the tumour volumes
were significantly larger from 36 to 74 days than the
tumour volumes from the Mock control treatment
group (Figure 5(a), left panel). The mice were sacrificed
74 days after the subcutaneous injection, and the
tumours were harvested. When the tumour weight
was measured, the αVβ3 sEV treatment group had
significantly heavier tumours compared to the Mock
sEV control group (Figure 5(a), right panel). IB analy-
sis of the xenograft lysates from the αVβ3 sEV treat-
ment group reveals a significant increase in the typical
NE markers such as AURKA, SYP and NSE, compared
to the Mock control group (Figure 5(b)). Remarkably,
sEVs do not contain the NE markers detected in the
xenografts (Figure 5(b), right panel). Proteomic analy-
sis of PC3 sEVs also confirms the absence of NE
markers (data not shown) [27]. IB analysis reveals an
increase in αVβ3 when the injected cells were treated
with αVβ3 sEVs (Figure 5(b) and 5(c), left panels), and
IHC analysis shows that αVβ3 is localized in the blood
vessels of the xenografts (Figure 5(c), right panel).
Bioinformatic analysis of a public dataset on
cBioPortal [19] reveals amplification of β3 integrin
(ITGB3), AURKA and SYP genes in at least 30% of
NEPrCa patients. In contrast, (ITGAV) or β6 (ITGB6)
integrin subunits were only amplified in 7% and 3%,
respectively (Figure 6(a)), indicating that amplification
of ITGB3, AURKA, and SYP genes may occur in
a subset of NEPrCa patients. Given previous reports
that metastatic lesions express αVβ3 [7,31,32], we ana-
lysed metastatic bone samples from PrCa patients using
IHC staining. We analysed 10 samples from eight dif-
ferent patients. When stained for αVβ3 integrin, seven
samples resulted in positive signals. Of the seven
αVβ3-positive samples, five were also positive for
SYP. Moreover, the three remaining samples that
were negative for β3 integrin were also negative
for SYP.
The αVβ3 integrin and SYP positive cells appeared
clustered and this made the quantitative comparison
difficult; however, in the positive cluster of tumour cells,
the staining was strong in >90% of the tumour cells.
Our results demonstrate co-expression of αVβ3 and
SYP in the metastatic bone lesions (Figure 6(b)). In
conclusion, our database analysis and IHC staining of
human samples indicate an upregulation of αVβ3 in
NE patients in agreement with our findings that αVβ3
sEV treatment induces NE in vitro and in vivo.
Finally, our group has previously reported increased
levels of αVβ3 integrin in the sEVs isolated from the plasma
of TRAMP mice [22], which develop progressive forms of
PrCa including NE cancer and metastasis at distant sites.
We confirm those findings here using differential centrifu-
gations to isolate sEVs from the plasma of TRAMPmice as
described in theMaterial andMethods section (Figure S3).
These sEVs did not contain CANX (data not shown).
These findings confirm an upregulation of circulating vesi-
cular αVβ3 in the plasma of TRAMP mice.
Discussion
Our results confirm that the expression of a single
integrin subtype, αVβ3, in sEVs affects the function
of these vesicles upon their uptake in recipient cells.
Specifically, we demonstrate in this study, for the first
time, that a single treatment with sEVs, isolated from
PrCa cells using iodixanol density gradients, signifi-
cantly stimulates tumour growth, and induces NED in
recipient cells both in vivo and in vitro. Our schematic
diagram in Figure 7 summarizes these findings.
We also demonstrate that this pathway is mediated by
the αVβ3 integrin expressed in the donor cells (C4-2B)
since this molecule is the only difference between
αVβ3-positive sEVs and Mock αVβ3-negative sEVs. The
upregulation of αVβ3 in the donor cells (C4-2B in this
study) may alter the cargo composition of the sEVs
released by the cells and enable them to induce NED in
the recipient cells. Previous examples of modulation of
sEV cargo by a drug or a single molecule have been
reported [35–37]. A recent publication [35] has also
shown that enzalutamide treatment of LNCaP cells stably
expressing AR induce changes in the sEV composition by
increasing the levels of BRN2 and BRN4 mRNA. Another
study [36] has shown that the upregulation of the tetra-
spanin Tspan8 in a breast cancer rat model changes sEV
composition by upregulation of E-cadherin and p120-
catenin in circulating rat plasma vesicles. Finally, RNA
sequencing and proteomic analysis of sEVs isolated from
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melanoma cells upon down-regulation of the insulin-like
growth factor 2 mRNA-binding protein 1 (IGF2BP1)
reveal differential expression of several mRNAs, proteins
and miRNAs [37]. We confirmed the presence of αVβ3
integrin in the sEVs through sEV immunocapturing on
a chip using Abs against CD81, CD63, and CD9 and
labelling the captured sEVs with a fluorescent Ab against
αVβ3 (Figure 2(a)). However, this integrin does not appear
to mediate sEV uptake in recipient cells since, when we
pre-treated the sEVs with an inhibitory Ab against αVβ3
integrin (LM609), anchorage-independent growth of reci-
pient cells was not affected (Figure 4(a)). Whether one, or
Figure 5. Tumour growth increase and induction of NE markers (AURKA, SYP, NSE) by αVβ3 sEVs in vivo. (a) αVβ3 sEV and
Mock sEV-treated DU145 cells (2.5 × 10 7cells/10 × 1010 sEVs) were injected subcutaneously in nude mice; the xenografts were
collected 74 days after injection. Time course of tumour growth was measured as tumour volume (left panel) or tumour weight
(right panel) 74 days after cell injection, as described in the Material and Methods section. P-values are indicated in the figure. (b)
Left panel, IB analysis for αVβ3, and NE markers: aurora kinase A (AURKA), synaptophysin (SYP), and neuron specific enolase (NSE) of
the xenografts. Lanes 1–4 are representative tumour lysates from the Mock sEV treatment, whereas lanes 5–8 are tumour lysates
from the αVβ3 sEV treatment group. Right panel, IB analysis of NE markers, AURKA and SYP, of the sEVs used to treat DU145 cells.
All IB analysis was performed under reducing conditions. (c) Left panel, immunohistochemical analysis of αVβ3-positive areas
(0.075 mm2) of the sEV-treated DU145 xenografts shown above. Right panels, representative images of the data quantified in the
left panel; IgG was used as negative control. The bar represents 10 μm.
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more, of the many pathways activated by αVβ3 is respon-
sible for the different cargo of the sEVs released by C4-2B
β3 and Mock cells remains to be established. For example,
it has been recently reported that the sole expression of
αVβ3 is associated with activation of the KRAS–RalB–NF-
κB pathway, indicating a role of αVβ3 in tumour stemness
and drug resistance [38]. Based on our findings, we spec-
ulate that a pro-NE component is differentially packaged
into the sEVs when αVβ3 is expressed in the donor cells.
Studies from our group and others have shown
dysregulation of the αVβ3 integrin in PrCa [13,14],
and that αVβ3 integrin in the tumour promotes angio-
genesis [29], cell migration [22,31], cell invasion [39],
and in general its expression correlates with low patient
survival [40]. However, its role in NEPrCa has not been
characterized. Based on the findings from our study, it
is reasonable to assume that sEVs released from cancer
cells that express αVβ3 integrin stimulate the
Figure 6. Upregulation of αVβ3 integrin in NEPrCa patients. (a) Bioinformatic analysis of public datasets. cBioPortal OncoPrint
graphic [33,34] showing the genomic alterations in ITGB3, AURKA, SYP, ITGAV and ITGB6 genes across the NEPrCa dataset containing
44 NEPrCa patient samples [19]. Glyphs and colour coding are used to summarize genomic alterations such as amplification (red).
Grey colour coding indicates no alterations. Benign tissues and blood samples were used as controls. (b) Representative image of
the immunohistochemical analysis for SYP and αVβ3 in PrCa bone (stern) metastasis. A total of 10 specimens from eight patients
were analysed. IgG was used as negative control. The bar represents 10 μm.
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surrounding cells to differentiate into a more aggres-
sive phenotype with NE characteristics. It should be
pointed out that while the expression of αVβ3 integrin
is required to generate pro-NE sEVs, αVβ3 is not
detected in the lysates of the PrCa cells that overexpress
NE markers, indicating that permanent expression of
αVβ3 is not required for the recipient cells to develop
NED (Figure 4(c)). Furthermore, αVβ3 sEVs do not
contain NE markers (Figure 5(b), right panel), indicat-
ing that the NE markers detected in recipient cells are
induced, and not transferred, by the αVβ3 sEVs.
It is still unclear how NED is induced in PrCa cells. The
ability to induce NE in PrCa using αVβ3 sEVs will open
new possibilities to study the mechanism of NED in PrCa.
A dominant NE marker, the serine/threonine kinase
AURKA, has been well studied, and its ability to promote
mitotic entry and cytokinesis has generated interest in
developing AURKA inhibitors as therapeutic targets in
prostate and breast cancers [41]. Indeed, the AURKA
gene is amplified in these cancers, as is also shown in our
analysis of NEPrCa. Furthermore, its transgenic
overexpression in mouse mammary epithelium induces
tetraploidy and centrosome amplification leading to breast
cancer development. It is known that overexpression of
AURKA in benign prostate cells induces SYP and NSE,
NE-specific markers, indicating a role of AURKA in mod-
ulating NED [42]. AURKA also stabilizes the transcription
factor N-MYC, one of the transcription factors important
in AR-independent CR NEPrCa (Rb1, p53, N-MYC), by
preventing its proteasomal degradation, and thus promot-
ing G1-S progression [43,44]. Regulation of AURKA by
sEVs or by integrins has never been shown, althoughmany
studies have described the mechanisms underlying integ-
rin regulation of cell cycle progression [45]. Specifically,
αVβ3 activation of cell cycle progression, as well as tumor-
igenesis, has been shown [46], and we thus envision activa-
tion of aberrant cell division upon αVβ3 sEV transfer to
recipient cells (Figure 7, schematic diagram).
Our analysis of the publicly-available database and
IHC staining of human samples confirms a positive asso-
ciation between β3 integrin subunit and NED in patients
(Figure 6); this analysis reveals gene amplification of β3
Figure 7. Schematic representation of the findings described in this study. The schematic diagram shows that the transfer of
sEVs from prostate cancer cells (C4-2B) expressing αVβ3 induces NED in the recipient cells (DU145, PC3, or LNCaP), whereas transfer
of Mock sEVs does not. The sEVs used in this study may have multiple origins (e.g., Multi Vesicular Body, MVB, or membrane
budding).
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integrin subunit, SYP, and AURKA in about 30% of
NEPrCa patients, suggesting that αVβ3 integrin is
involved in NED. It is possible that the cells from the
metastatic lesions that overexpress αVβ3 (Figure 6(b))
release αVβ3 positive sEVs (similar to those characterized
in this study) that in turn induce NED in the primary
tumour. Although we are not implying that sEVs mediate
genomic events, EV mediated transfer represents another
way for these molecular markers to be co-expressed.
Because treatment with αVβ3 sEVs increases NED in
the recipient cells, and our previous study showed an
increase in αVβ3 EVs isolated from blood plasma of
patients affected by PrCa [5], a therapeutic approach
that targets αVβ3 might be an effective strategy against
NEPrCa [47]. Moreover, αVβ3-positive sEVs might serve
as a suitable biomarker to predict NED in PrCa patients.
Another implication of our study is that sEVs contain-
ing αVβ3 might be used to target the tumour microenvir-
onment enriched in αVβ3 ligands. Our study adds value
to recent research, which has demonstrated that increased
levels of αVβ3 and its ligands can be used to target cancer
cells. In one study, Ross et al. were able to inhibit tumour
growth in αVβ3-positive bone metastasis from breast
cancer by using nanoparticles (~12.5 nm) coated with
a specific αVβ3 ligand and loaded with a microtubule
inhibitor [48]. Moreover, they were able to detect the
induction of αVβ3 integrin in the metastatic lesions. In
another study, Tian et al. were able to confer organ
specificity to sEVs by inducing the expression of lyso-
some-associated membrane glycoprotein 2b (Lamp2b)
fused with an iRGD peptide [49], a well-known ligand
for αVβ3 [50], as previosly described by Sugahara et al.
[51]. In Tian et al. study, the investigators were able to
specifically deliver doxorubicin into breast cancer cells,
which resulted in a significant inhibition of tumour
growth, by using circulating Lamp2b-iRGD sEVs [49].
Androgen deprivation therapy is currently the stan-
dard-of-care treatment for PrCa; however, once the can-
cer acquires castrate resistance, it invariably becomes
lethal. It is still not clear how AR regulates NED.
Previous studies have shown that NED is frequently
associated with AR deprivation [42,52], although one
study reported AR amplification in therapy-resistant
CRPrCa [53]. In our studies here, αVβ3 sEV treatment
causes downregulation of AR in LNCaP cells in associa-
tion with increased SYP expression, indicating that under
the conditions used in our experiments, AR depletion
may be necessary for NED to be induced. Further study
of the involvement of AR in NED is necessary, especially
in view of our evidence showing that sEVs may modulate
AR levels in recipient cells.
In conclusion, here we show that the expression of
a single molecule in the donor cells affects the function
of secreted sEVs. The novelty of these findings lies in
our evidence that αVβ3 sEVs reprogram PrCa cells
towards a NE phenotype, thus demonstrating that
released sEVs regulate a critical step in PrCa
progression.
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